Drug Trial Radar · NCT06945419
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
219
Actual
Start
Apr 23, 2025
Primary completion
Aug 5, 2026
Study completion Aug 5, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Apr 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Conditions
- Healthy
- Overweight
- Obesity
- Type 2 Diabetes
Interventions
LY4086940Drug
Administered orally
PlaceboDrug
Administered orally
LY4086940Drug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to Week 9
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit
Daytona Beach, Florida
Clinical Pharmacology of Miami
Miami, Florida
Fortrea Clinical Research Unit
Dallas, Texas
Endeavor Clinical Trials
San Antonio, Texas
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.